Please enable Javascript on your browser for a better experience.
The MDMA Urine Drug Screen detects the presence of MDMA (ecstasy) and related metabolites in urine above defined cutoff levels using immunoassay screening. This test offers an initial evaluation of recent MDMA use in clinical, treatment, or monitoring settings. A positive result indicates detection beyond threshold levels, but does not include confirmatory testing in this version.
The MDMA/MDA Urine Drug Screen with Confirmation begins with a broad immunoassay screen for MDMA and its metabolite MDA, then applies confirmatory testing (e.g. mass spectrometry) to validate positives. This two-step approach enhances specificity and ensures that detected substances are correctly identified, providing reliable verification of ecstasy (MDMA/MDA) use in clinical or monitoring settings.
The MDMA/MDA Urine Drug Test quantitatively measures concentrations of MDMA (ecstasy) and its metabolite MDA in urine using precise analytical instrumentation. This test goes beyond mere detection to report actual levels, offering clinicians and monitoring programs deeper insight into dosage, exposure trends, and compliance in drug use assessment.
The Panel 5 Urine Drug Screen detects multiple commonly abused drugs in urine using immunoassay screening at established cutoff levels. As a standard 5-panel test, it covers core substances like amphetamines, opioids, cocaine, cannabis, and PCP to provide a foundational assessment of substance exposure in clinical, workplace, or monitoring contexts. Positive findings may indicate the presence of one or more drugs.
The Amphetamines Urine Drug Screen with Confirmation and D/L Isomers first screens for amphetamine compounds, then applies confirmatory testing that distinguishes D- and L-methamphetamine isomers. This test combines detection, verification, and isomer differentiation to offer more precise insight in clinical, legal, or monitoring settings.
The Cocaine Urine Drug Screen detects the presence of benzoylecgonine (a primary cocaine metabolite) in urine above threshold levels using immunoassay screening. This test serves as an initial assessment of recent cocaine use in clinical, treatment, or monitoring settings. Detection indicates use beyond cutoff but does not include confirmatory testing in this version.
The Cocaine Urine Drug Screen with Confirmation combines an initial immunoassay screen for cocaine metabolites with confirmatory testing to verify positive findings. This two-step approach ensures both detection and validation of cocaine use in urine, improving specificity and confidence of results for clinical, legal, or monitoring applications.
The Alcohol Urine Drug Test quantitatively measures ethyl glucuronide (EtG) and ethyl sulfate (EtS) levels in urine to assess recent alcohol intake. This precise quantitative analysis enables clinicians and monitoring programs to track consumption patterns over time, distinguish between trace exposure and significant use, and support reliable alcohol monitoring in clinical, treatment, or legal settings.
The Amphetamines Urine Drug Screen detects the presence of amphetamine and related compounds in urine above defined cutoff levels. This screening test provides an initial assessment of recent amphetamine use and is commonly applied in workplace, treatment, and clinical monitoring contexts. Results indicate detection at or above threshold limits but are not confirmed by additional testing.
The Amphetamines Urine Drug Screen with Confirmation combines initial screening and confirmatory testing to detect and verify the presence of amphetamines in urine. This method delivers both sensitivity and specificity, ensuring positive results are validated. Ideal for clinical, legal, or monitoring settings, it supports reliable reporting of amphetamine use.
The Barbiturates Urine Drug Screen detects the presence of barbiturate compounds in urine above established cutoff levels, using immunoassay methodology. This screening test is used in clinical, treatment, and monitoring settings to identify barbiturate use. A positive result indicates detection but does not include confirmatory testing, so results should be interpreted in context.
The Barbiturates Urine Drug Screen with Confirmation performs an initial immunoassay screening for barbiturates and then confirms positives using mass spectrometry. It verifies the presence of barbiturate drugs like phenobarbital, pentobarbital, secobarbital, and more. Designed for clinical, legal, or treatment monitoring, it delivers both detection and validation for greater confidence in results.
The Base Panel Urine Drug Screen screens a multi-drug panel in urine using immunoassay methods to detect commonly monitored substances above threshold levels. The panel includes drugs such as amphetamines, benzodiazepines, cocaine, opioids, and more. This broad screening test is widely used in clinical, workplace, and monitoring settings for initial detection across multiple drug classes.
The Base Panel Urine Drug Screen with Confirmation combines an initial multi-drug immunoassay screen with confirmatory testing to validate positive findings. It detects common substances across multiple drug classes in urine, then uses advanced analysis to confirm the presence of specific analytes. This dual approach boosts accuracy and confidence in results for clinical or monitoring settings.
The Benzodiazepines Urine Drug Screen detects the presence of benzodiazepine compounds in urine above established cutoff levels using immunoassay techniques. This screening test identifies recent use of medications like diazepam, alprazolam, or lorazepam in clinical, treatment, or monitoring settings. Positive results indicate detection at threshold levels but are not confirmed by additional testing.
The Benzodiazepines Urine Drug Screen with Confirmation performs an initial screening for benzodiazepine compounds in urine, followed by confirmatory testing to validate positive results. This process ensures reliable identification of drugs like diazepam, lorazepam, or alprazolam in clinical or monitoring settings, adding confidence and specificity to benzodiazepine detection.
The Buprenorphine Urine Drug Screen detects the presence of buprenorphine and its metabolites in urine above established cutoff levels using immunoassay screening methods. This test is commonly used in treatment, clinical monitoring, and compliance settings to identify recent buprenorphine use. Positive results reflect detection, but do not include confirmatory testing.
The Cocaine Urine Drug Test quantitatively measures the concentration of benzoylecgonine (the primary cocaine metabolite) in urine using high-precision analytical methods. This quantitative analysis provides more than detection—it reveals the level of cocaine exposure to support clinical monitoring, compliance evaluation, or detailed case review over time.
The Fentanyl Urine Drug Screen detects the presence of fentanyl and its metabolites in urine above established cutoff levels using immunoassay screening methods. This test provides an initial assessment of opioid exposure, useful in clinical, monitoring, or treatment settings. A positive result indicates detection but does not include confirmatory testing.
The Fentanyl Urine Drug Screen with Confirmation performs an initial immunoassay screening for fentanyl and then applies confirmatory testing (e.g. mass spectrometry) to verify positive results. This two-step process reduces false positives and ensures specificity in detecting fentanyl use in urine for clinical or monitoring programs.
The Heroin Urine Drug Screen detects the presence of heroin metabolites (such as 6-monoacetylmorphine) in urine above established cutoff levels, using immunoassay screening. This test provides a first-line assessment of recent heroin use in clinical, monitoring, or treatment settings. A positive result indicates detection but does not include confirmatory testing.
The Heroin Urine Drug Screen with Confirmation begins with an immunoassay screen for heroin metabolites (such as 6-monoacetylmorphine), then reflexes positives to mass spectrometry confirmation. This two-step approach ensures both sensitivity and specificity, validating the presence of heroin use in urine and reducing false positives for clinical or monitoring purposes.
The Marijuana Urine Drug Screen detects THC metabolites (such as THC-COOH) in urine above established cutoff levels using immunoassay screening methods. This test provides an initial indication of recent cannabis use in clinical, monitoring, or workplace settings. A positive result signals detection above threshold, but confirmatory testing is not part of this version.
The Marijuana Urine Drug Screen with Confirmation performs an initial immunoassay screen for THC metabolites (such as THC-COOH) in urine, followed by confirmatory testing to validate any positive findings. This two-step testing approach ensures both sensitivity and specificity, providing reliable confirmation of cannabis use in clinical, monitoring, or compliance settings.
The Methadone Urine Drug Screen detects the presence of methadone metabolites in urine above defined cutoff levels using immunoassay screening methods. This test provides a first-pass assessment of methadone use in clinical, monitoring, or treatment settings. Positive results indicate detection beyond threshold limits, but no confirmatory steps are included in this test version.
